A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer (NCT05483868)

🧪 Interventions in This Study

• AU-011 (DRUG)
• AU-011 in Combination with Medical Laser Adminstration (COMBINATION_PRODUCT)
• AU-011 in Combination with Medical Laser Administration (COMBINATION_PRODUCT)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (19 Sites)

• Arkansas Urology — Little Rock, Arkansas
• Tower Urology — Los Angeles, California
• Saint John's Cancer Institute — Santa Monica, California
• Colorado Clinical Research — Lakewood, Colorado
• Montefiore Medical Center — The Bronx, New York
• UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
• Carolina Urologic Research Center — Myrtle Beach, South Carolina
• Urology Associates, P.C. — Nashville, Tennessee
• Urology Clinics of North Texas — Dallas, Texas
• Baylor College of Medicine — Houston, Texas
• The University of Texas San Antonio — San Antonio, Texas
• Urology San Antonio/USA Clinical Trials — San Antonio, Texas
• The Urology Place — San Antonio, Texas
• Westmead Private Hospital — Westmead, New South Wales
• Austin Health — Heidelberg, Victoria
• Warringal Private Hospital — Heidelberg, Victoria
• Penninsula Private Hospital — Langwarrin, Victoria
• The Royal Melbourne Hospital — Parkville, Victoria
• Hollywood Private Hospital — Nedlands, Western Australia

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-muscle-invasive Bladder Cancer

• Intravesical BCG vs GEMDOCE in NMIBC — Birmingham, Alabama
• Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer — Auchenflower,
• Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance — West Haven, Connecticut
• Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC) — Dallas, Texas
• A Phase I Intravesical PPM Therapy for NMIBC — Boston, Massachusetts

Explore by condition: All Non-muscle-invasive Bladder Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.